Oncostatin M As a Potential Molecular Target in Systemic Sclerosis
Maria Feeney, CP Denton(The Royal Free Hospital), A Holmes, Khaleque Newaz Khan(Nagasaki University), Sarah L. Trinder(Queen Mary University of London), Farhan Syed(University Hospital Coventry), Suyun Xu(University of Shanghai for Science and Technology), David Abraham(Thomas Jefferson University)
UCL Discovery (University College London)
October 1, 2015
Cited by 4
Related Papers
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach
|Annals of the Rheumatic Diseases|2003|769
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503
Open-Label Trial of Anti-TNF-α in Dermato- and Polymyositis Treated Concomitantly with Methotrexate
|European Neurology|2008|99
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test
|Annals of the Rheumatic Diseases|2006|98